Hormones and Metabolic Modulators

WADA Prohibited List (January 1, 2026)

S4 - HORMONES AND METABOLIC MODULATORS

The following hormone and metabolic modulators are prohibited:

1. Aromatase inhibitors including, but not limited to: 2-Androstenol (5α-androst-2-en-17-ol); 2-Androstenone (5α-androst-2-en-17-one); 3-Androstenol (5α-androst-3-en-17-ol); 3-Androstenone (5α-androst-3-en-17-one); 4-Androstene-3,6,17-trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone
    
2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Bazedoxifene; Clomifene; Cyclofenil; Fulvestrant; Ospemifene; Raloxifene; Tamoxifen; Toremifene
    
3. Agents preventing activin receptor IIB activation, including, but not limited to: Activin A-neutralizing antibodies; Activin receptor IIB competitors such as: Decoy activin receptors (e.g., ACE-031); Anti-activin receptor IIB antibodies (e.g., Bimagrumab); Myostatin inhibitors such as: Agents reducing or ablating myostatin expression; Myostatin-binding proteins (e.g., follistatin, myostatin propeptide); Myostatin-neutralizing antibodies (e.g., domagrozumab, landogrozumab, stamulumab)
    
4. Metabolic modulators:
   4.1
   • Activators of AMP-activated protein kinase (AMPK), e.g., 5-N,6-N-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine (BAM15), AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) 
   • Peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g., 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy)acetic acid (GW1516, GW501516) 
   • Rev-erbα agonists, e.g., SR9009, SR9011
   4.2 Insulins and insulin mimetics, e.g., S519, S597
   4.3 Meldonium
   4.4 Trimetazidine

• See also WADA Prohibited List

History

Name of the group until the end of 2007: Substances with antiestrogenic effects

Name of the group from 2008: Hormone antagonists and modulators

The group of substances with antiestrogenic effects was expanded and renamed as of January 1, 2008, with the inclusion of substances that can influence the function of myostatin (so-called myostatin inhibitors and similar compounds).

See also information on myostatin and myostatin inhibitors

Group name as of 2012: Hormones and Metabolic Modulators

Starting in 2012, an additional group was added: 5. Metabolic Modulators—This includes substances such as GW1516 and AICAR, which were previously banned under the genetic doping category.

Starting in 2013, Group 5 was expanded to include the peptide hormone insulin, which had previously been listed under Group S2 Peptide Hormones.

As of 2016, the substance meldonium was banned under 5.3.

As of 2018, trimetazidine, which was previously listed in Group S6 (Stimulants), was added under 5.4.

Note: The term "estrogen" is often spelled in various ways: Östrogen - Antiöstrogen; Oestrogen - Antioestrogen; Estrogen - Antiestrogen